- Anti-Viral Drugs
- Targeted Therapy
- Immunosuppressant Drugs
- Chemotherapy Drugs
- Immunoglobulin
- Other Treatment Types
Liver Disease Treatment Market size was valued at USD 19,634,9 million in 2023 and is poised to grow at an 6.3% CAGR from 2024 to 2030. Cancer, hepatitis, autoimmune diseases, and genetic disorders are some common liver diseases. These diseases are commonly caused by infections, genetics, obesity, diabetes, and immune system abnormalities. The rising geriatric population, which is susceptible to various chronic ailments, including liver disease, across the globe is one of the prime factors driving the growth of the liver disease treatment market. The changing dietary patterns and sedentary lifestyles as well as the increasing prevalence of fatty liver disease due to high cholesterol, obesity, hypertension (high blood pressure), and diabetes are favoring the liver disease treatment market growth. Moreover, various technological advancements, such as the development of the bioartificial liver, are providing an impetus to the liver disease treatment market. It utilizes regenerated liver cells to replace liver functions and is widely used for acute liver failure patients. With the increased demand for liver disease treatments, major players have invested capital in researching and developing better drugs, devices, and treatment options.
For example, in December 2020, the American biopharmaceutical corporation Gilead Sciences, Inc. announced the acquisition of MYR GmbH, a German healthcare organization focused on discovering and commercializing therapies for treating chronic liver disease. Gilead declared its intention to buy MYR for approximately USD 1.36 billion in cash. Other such developments and advancements in the liver disease treatment market will make the industry competitive and help it become more efficient, providing the necessary impetus to its growth and lucrative opportunities for the market players. However, considering the high initial investment as well as sum of money needed to purchase the medications and therapies used to treat liver disorders and related conditions are expected to limit the growth of the liver disease treatment market. Moreover, stringent government regulations and guidelines are expected to hamper the growth of the liver disease treatment market. Ongoing trends such as the rapid adoption of antiviral drugs as they are safe and effective, assist in suppressing the hepatitis B virus, and help in reducing the risk of developing cirrhosis and hepatocellular carcinoma, is positively impacting the liver disease treatment market growth.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
An increase in screen time combined with a sedentary lifestyle, no physical exercise & unhealthy diet has led to an increase in the number of individuals suffering from liver diseases. The growing geriatric population has witnessed an increasing prevalence of liver diseases like hepatitis, non-alcoholic fatty liver, and other autoimmune diseases. Increasing alcohol consumption has also contributed significantly to the growing number of patients. Various treatments are deployed to treat the ever-increasing number of patients suffering from liver-related diseases caused by unhealthy lifestyles, unhealthy diets, heavy alcohol consumption, or old age, which will drive the global liver disease treatment market.
Liver Disease Treatment Market was valued at USD 19,634,9 million in 2023 and is expected to grow at an 6.3% CAGR from 2024 to 2030.
Abbott Laboratories, Bristol-Myers Squibb Company, Gilead Sciences, GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi AG, and AbbVie Inc. are some of the major players operating in the liver disease treatment market.
The Anti-Viral Drugs segment is expected to dominate the market during the forecast period.
North America accounts for the largest market share and is expected to be the primary market driver in the liver disease treatment market.
Non-Alcoholic fatty Liver disease is the most common causes of liver disease globally.
1.Executive Summary |
2.Global Liver Disease Treatment Market Introduction |
2.1.Global Liver Disease Treatment Market - Taxonomy |
2.2.Global Liver Disease Treatment Market - Definitions |
2.2.1.Treatment |
2.2.2.Disease Type |
2.2.3.Distribution Channel |
2.2.4.Region |
3.Global Liver Disease Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Liver Disease Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Liver Disease Treatment Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Anti-Viral Drugs |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Targeted Therapy |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Immunosuppressant Drugs |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Chemotherapy Drugs |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Immunoglobulin |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Other Treatment Types |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6.Global Liver Disease Treatment Market By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Hepatitis |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Autoimmune Diseases |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Non-Alcoholic Fatty Liver Disease (NAFLD) |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Cancer |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Genetic Disorders |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Others |
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
7.Global Liver Disease Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospitals |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Ambulatory Surgical Centers |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Others |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Liver Disease Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Liver Disease Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Anti-Viral Drugs |
9.1.2.Targeted Therapy |
9.1.3.Immunosuppressant Drugs |
9.1.4.Chemotherapy Drugs |
9.1.5.Immunoglobulin |
9.1.6.Other Treatment Types |
9.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hepatitis |
9.2.2.Autoimmune Diseases |
9.2.3.Non-Alcoholic Fatty Liver Disease (NAFLD) |
9.2.4.Cancer |
9.2.5.Genetic Disorders |
9.2.6.Others |
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospitals |
9.3.2.Ambulatory Surgical Centers |
9.3.3.Others |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Liver Disease Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Anti-Viral Drugs |
10.1.2.Targeted Therapy |
10.1.3.Immunosuppressant Drugs |
10.1.4.Chemotherapy Drugs |
10.1.5.Immunoglobulin |
10.1.6.Other Treatment Types |
10.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hepatitis |
10.2.2.Autoimmune Diseases |
10.2.3.Non-Alcoholic Fatty Liver Disease (NAFLD) |
10.2.4.Cancer |
10.2.5.Genetic Disorders |
10.2.6.Others |
10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospitals |
10.3.2.Ambulatory Surgical Centers |
10.3.3.Others |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Liver Disease Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Anti-Viral Drugs |
11.1.2.Targeted Therapy |
11.1.3.Immunosuppressant Drugs |
11.1.4.Chemotherapy Drugs |
11.1.5.Immunoglobulin |
11.1.6.Other Treatment Types |
11.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hepatitis |
11.2.2.Autoimmune Diseases |
11.2.3.Non-Alcoholic Fatty Liver Disease (NAFLD) |
11.2.4.Cancer |
11.2.5.Genetic Disorders |
11.2.6.Others |
11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospitals |
11.3.2.Ambulatory Surgical Centers |
11.3.3.Others |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Liver Disease Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Anti-Viral Drugs |
12.1.2.Targeted Therapy |
12.1.3.Immunosuppressant Drugs |
12.1.4.Chemotherapy Drugs |
12.1.5.Immunoglobulin |
12.1.6.Other Treatment Types |
12.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hepatitis |
12.2.2.Autoimmune Diseases |
12.2.3.Non-Alcoholic Fatty Liver Disease (NAFLD) |
12.2.4.Cancer |
12.2.5.Genetic Disorders |
12.2.6.Others |
12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospitals |
12.3.2.Ambulatory Surgical Centers |
12.3.3.Others |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Liver Disease Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Anti-Viral Drugs |
13.1.2.Targeted Therapy |
13.1.3.Immunosuppressant Drugs |
13.1.4.Chemotherapy Drugs |
13.1.5.Immunoglobulin |
13.1.6.Other Treatment Types |
13.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Hepatitis |
13.2.2.Autoimmune Diseases |
13.2.3.Non-Alcoholic Fatty Liver Disease (NAFLD) |
13.2.4.Cancer |
13.2.5.Genetic Disorders |
13.2.6.Others |
13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospitals |
13.3.2.Ambulatory Surgical Centers |
13.3.3.Others |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Abbott Laboratories |
14.2.2.Astellas Pharma Inc. |
14.2.3.Bristol-Myers Squibb Company |
14.2.4.Gilead Sciences |
14.2.5.GlaxoSmithKline PLC |
14.2.6.Hoffmann-La Roche Ltd. |
14.2.7.Merck & Co. Inc. |
14.2.8.Novartis AG |
14.2.9.Sanofi AG |
14.2.10.AbbVie Inc. |
14.2.11.Endo International PLC |
14.2.12.Pfizer Inc. |
14.2.13.Takeda Pharmaceutical |
14.2.14.Alnylam Pharmaceuticals Inc. |
14.2.15.Provectus Biopharmaceuticals Inc. |
15. Research Methodology |
16. Appendix and Abbreviations |